Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune ...
People also ask
What does Landos Biopharma do?
Is AbbVie acquiring autoimmune startup Landos Biopharma?
Who is the founder of Landos Biopharma?
Mar 25, 2024 · Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC).
Mar 25, 2024 · Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC).
Mar 26, 2024 · AbbVie has entered into a definitive agreement for the acquisition of Landos Biopharma, in a deal totalling $212.5m.
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases.